- GlobeNewswire•11 days ago
SEATTLE, March 13, 2017-- Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company’ s Board of Directors. Azelby ...
- Associated Press•15 days ago
On a per-share basis, the Seattle-based company said it had a loss of 47 cents. For the year, the company reported that its loss widened to $57.7 million, or $3.13 per share. In the final minutes of trading ...
- GlobeNewswire•15 days ago
SEATTLE, March 09, 2017-- Cascadian Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2016.. “In 2016, we focused our efforts on the development ...
CASC : Summary for Cascadian Therapeutics, Inc. - Yahoo Finance
Cascadian Therapeutics, Inc. (CASC)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.15 x 100|
|Ask||6.29 x 100|
|Day's Range||3.79 - 4.10|
|52 Week Range||0.82 - 6.72|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.30|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|